Efficacy and Safety of Ibuprofen in Infants Aged Between 3 and 6 Months

Victoria C Ziesenitz1,2, Andreas Zutter3, Thomas O Erb3

  • 1Division of Paediatric Pharmacology and Pharmacometrics, University of Basel Children's Hospital, Spitalstrasse 33, 4056, Basel, Switzerland. Ziesenitz.md@gmail.com.

Paediatric Drugs
|May 19, 2017
PubMed

Insights

Ibuprofen (a non-steroidal anti-inflammatory drug) is safe for short-term use in infants over 3 months old for fever and pain relief when dosed by weight. Rectal administration is less reliable in infants.

Area of Science:

  • Pediatrics
  • Pharmacology

Background:

  • Ibuprofen is a widely used non-steroidal anti-inflammatory drug (NSAID) for pediatric fever and pain relief.
  • Dosing recommendations for infants, particularly those aged 3-6 months, vary, necessitating further clarity.

Purpose of the Study:

  • To assess the safety and efficacy of ibuprofen in infants.
  • To determine optimal pain and fever management strategies for infants using ibuprofen.

Main Methods:

  • Review of current evidence on ibuprofen use in infants.
  • Analysis of safety and efficacy data, focusing on age and weight parameters.

Main Results:

  • Short-term ibuprofen use is safe in infants >3 months and >5-6 kg with adequate hydration.
  • Recommended dosage is 5-10 mg/kg per administration, 3-4 times daily (max 30-40 mg/kg/day).
  • Rectal absorption of ibuprofen in infants is erratic and less reliable.

Conclusions:

  • Ibuprofen is safe for short-term use in infants over 3 months and 5-6 kg, with careful attention to hydration.
  • Weight-based dosing (5-10 mg/kg) is recommended.
  • Further research is needed on ibuprofen's efficacy for pain management in young infants.

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
445
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
392
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
293
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
341
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
387